Foundation Medicine has partnered with Syndax Pharmaceuticals to develop a diagnostic tool for acute myeloid leukemia (AML) patients with an NPM1 mutation.
The partnership aims to identify AML patients with NPM1 mutations and to develop a companion diagnostic based on the FoundationOne Heme platform. This could potentially increase access to targeted therapies such as Syndax's drug revumenib for AML patients with this specific mutation. If approved, it could potentially be the first next-generation sequencing companion diagnostic for hematologic neoplasms. Syndax has also agreed to support Foundation Medicine's regulatory approval process for this diagnostic assay.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.